Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a disease in which motor nerve cells degenerate, resulting in rapidly progressing muscle weakness, paralysis, and respiratory failure.
Amylyx’s therapeutic candidate AMX0035 is currently undergoing evaluation as a potential disease-modifying treatment for ALS in the Centaur Trial, supported by the ALS Association and ALS Finding a Cure.
Alzheimer’s disease causes the degeneration of nerve cells in the brain’s memory centers, resulting in progressive memory and functional loss. It is the most common form of dementia.
Amylyx’s therapeutic candidate AMX0035 is currently undergoing evaluation as a potential disease-modifying treatment for ALS in the Pegasus Clinical Trial, supported by the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation.
October 24, 2017
Innovative Alzheimer’s Disease Combination Therapy Trial Supported By New Joint Funding Initiative
The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of ALS
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS).
Project ALS and Amylyx Enter Collaboration to Test AMX0035
Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral compound AMX0035 to advance the understanding of the compound’s neurobiological effects.